Purple Biotech Reports Fourth Quarter and Full Year 2025 Financial Results

Core Insights - The company is focusing on the development of tri-specific antibodies from the CAPTN-3 platform, specifically IM1240 and IM1305, targeting tumor-associated antigens 5T4 and TROP2 respectively [1][2] - Positive preclinical data indicates multi-arm anti-tumor activity for both IM1240 and IM1305, with an expanded therapeutic window and commercially viable yield achieved for IM1240 [1][3] - The company reported a total cash position of $9.5 million as of December 31, 2025, which is expected to provide operational runway into 2027 [1][13] Development Highlights - The CAPTN-3 platform has shown significant and sustained tumor regression across IM1240 and IM1305, with transcriptomic analysis supporting the inclusion of the NKG2A arm in designs [6][7] - IM1240 demonstrated improved tolerability in toxicology studies, with doses up to 300-fold higher than a non-capped comparator, and significantly reduced immune-related toxicity [6] - Manufacturing milestones for IM1240 have been achieved, positioning the program competitively for future development [5] Financial Performance - For the three months ended December 31, 2025, research and development expenses increased to $1.8 million from $0.5 million in the same period of 2024, primarily due to CAPTN-3 platform development activities [8] - General and administrative expenses rose to $1.1 million compared to $0.6 million in the same period of 2024, attributed to increased professional services fees [9] - The company recognized a $20.5 million impairment loss related to in-process research and development assets CM24 and NT219, reflecting a strategic focus on the CAPTN-3 platform [10][15] Loss and Cash Flow - The operating loss for the year ended December 31, 2025, was $27.5 million, an increase from $11 million in 2024, primarily due to the impairment expenses [16] - The net loss for the year was $26.4 million, or $54.9 loss per basic ADS, compared to a net loss of $7.2 million in 2024 [17] - Cash and cash equivalents at the end of 2025 were $8.7 million, up from $7.4 million at the end of 2024, indicating a net increase in cash flow [30]